No Data
Do Its Financials Have Any Role To Play In Driving Guangdong Taienkang Pharmaceutical Co., Ltd.'s (SZSE:301263) Stock Up Recently?
Taienkang Pharmaceutical Unit Gets Acceptance for Eye Drop Production Registration
Tai'enkang (301263.SZ): The application for the registration and marketing authorization of Diquafosol Sodium Eye Drops has been accepted.
Tai En Kang (301263.SZ) announced that its wholly-owned subsidiary ShanDong Hua Bo Kai Sheng Biotechnology Co., Ltd. recently...
Tainkang (301263.SZ): The wholly-owned subsidiary has completed the enrollment of the first subject for the lidocaine and prilocaine aerosol project.
On February 18, Gelonghui reported that Tai En Kang (301263.SZ) announced that its wholly-owned subsidiary, ShanDong Hua Bo Kai Sheng Biotechnology Co., Ltd., recently organized the completion of the first subject recruitment for the Phase III clinical trial of lidocaine and prilocaine aerosol. This Phase III trial for lidocaine and prilocaine aerosol aims to verify its effectiveness and safety in treating primary PE in adult males, and has received approval from the ethics committee of the research center, successfully completing the first subject recruitment recently.
Why We're Not Concerned About Guangdong Taienkang Pharmaceutical Co., Ltd.'s (SZSE:301263) Share Price
Tai En Kang (301263.SZ): Application for the registration of Pharmaceutical Labetalol Hydrochloride Tablets has been accepted.
Tai En Kang (301263.SZ) announced that its wholly-owned subsidiary ShanDong Hua Bo Kai Sheng Biotechnology Co., Ltd. recently...
Cautious Investors Not Rewarding Guangdong Taienkang Pharmaceutical Co., Ltd.'s (SZSE:301263) Performance Completely